HRP20130144T4 - Inhibitori renina - Google Patents
Inhibitori renina Download PDFInfo
- Publication number
- HRP20130144T4 HRP20130144T4 HRP20130144TT HRP20130144T HRP20130144T4 HR P20130144 T4 HRP20130144 T4 HR P20130144T4 HR P20130144T T HRP20130144T T HR P20130144TT HR P20130144 T HRP20130144 T HR P20130144T HR P20130144 T4 HRP20130144 T4 HR P20130144T4
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- alkyl
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 239000002461 renin inhibitor Substances 0.000 title 1
- 229940086526 renin-inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 8
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 claims 6
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 claims 6
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 claims 6
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 claims 6
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 claims 6
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 claims 6
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 claims 6
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 claims 6
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 230000009977 dual effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000002160 alpha blocker Substances 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 206010062886 Procedural hypertension Diseases 0.000 claims 1
- 108090000783 Renin Proteins 0.000 claims 1
- 102100028255 Renin Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108010020708 plasmepsin Proteins 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000894 saliuretic effect Effects 0.000 claims 1
- MXNWARAWBOJCJF-NEPJUHHUSA-N tert-butyl n-[(2s)-1-amino-3-[(3r)-oxan-3-yl]propan-2-yl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)[C@H](CN)C[C@H]1CCCOC1 MXNWARAWBOJCJF-NEPJUHHUSA-N 0.000 claims 1
- VGDTYMGMGAROSF-MNOVXSKESA-N tert-butyl n-[(2s)-1-amino-3-[(3r)-oxan-3-yl]propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CN)C[C@H]1CCCOC1 VGDTYMGMGAROSF-MNOVXSKESA-N 0.000 claims 1
- MXNWARAWBOJCJF-UHFFFAOYSA-N tert-butyl n-[1-amino-3-(oxan-3-yl)propan-2-yl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C(CN)CC1CCCOC1 MXNWARAWBOJCJF-UHFFFAOYSA-N 0.000 claims 1
- VGDTYMGMGAROSF-UHFFFAOYSA-N tert-butyl n-[1-amino-3-(oxan-3-yl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CN)CC1CCCOC1 VGDTYMGMGAROSF-UHFFFAOYSA-N 0.000 claims 1
- 230000006444 vascular growth Effects 0.000 claims 1
- -1 β-10 blocker Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (20)
1. Spoj koji je prikazan sa slijedećom strukturnom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
R1 je alkil, cikloalkil ili cikloalkilalkil;
R2 je H ili alkil;
R3 je F, Cl, Br, cijano, nitro, alkil, haloalkil, alkoksi, haloalkoksi, ili alkansulfonil; te
n je 0, 1, 2, ili 3.
2. Spoj prema zahtjevu 1, naznačen time da:
R1 je (C1-C3)alkil;
R2 je H ili (C1-C3)alkil;
R3 je F, Cl, Br, cijano, nitro, (C1-C3)alkil, halo(C1-C3)alkil, (C1-C3)alkoksi, halo(C1-C9)alkoksi, ili (C1-C3)alkansulfonil; te
n je 0, 1, 2, ili 3.
3. Spoj prema zahtjevu 1, naznačen time da je spoj prikazan sa slijedećom strukturnom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
R1 je (C1-C3)alkil;
R2 je H ili (C1-C3)alkil;
R3 je F, Cl, Br, cijano, nitro, (C1-C3)alkil, halo(C1-C3)alkil, (C1-C3)alkoksi, halo(C1-C3)alkoksi, ili (C1-C3)alkansulfonil; i
n je 0, 1, 2, ili 3.
4. Spoj prema bilo kojem od zahtjeva 1-3, naznačen time da R1 je metil i R2 je H ili metil.
5. Spoj prema zahtjevu 1 ili 3, naznačen time da R3 je F, Cl, ili metil i n je 1 ili 2.
6. Spoj prema zahtjevu 1, naznačen time da je spoj prikazan sa strukturnom formulom koja je odabrana od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 1 naznačen time da je prikazan sa slijedećom strukturnom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema zahtjevu 1 koji je prikazan sa slijedećom strukturnom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da je spoj barem 90% optički čist.
9. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač ili razrjeđivač i spoj prema bilo kojem od zahtjeva 1-8.
10. Farmaceutski pripravak prema zahtjevu 9, naznačen time da dodatno sadrži α-blokator, β-10.blokator, blokator kalcijevog kanala, diuretik, natriuretik, saluretik, centralno djelujući antihipertenziv, inhibitor angiotenzin konvertirajućeg enzima, dvostruki angiotenzin konvertirajući enzim i neutralni inhibitor endopeptidaze, blokator receptora angiotenzina, dvostruki blokator receptora angiotenzina i antagonista receptora endotelina, inhibitor aldosteron sintaze, antagonist receptora aldosterona, ili antagonist receptora endotelina.
11. Spoj prema bilo kojem od zahtjeva 1-8 naznačen time da je za antagoniziranje jedne ili više aspartatnih proteaza.
12. Spoj prema zahtjevu 11, naznačen time da aspartatna proteaza je renin.
13. Uporaba spoja prema bilo kojem od zahtjeva 1-8 naznačena time da je za proizvodnju lijeka za antagoniziranje jedne ili više aspartatnih proteaza kod subjekta kojemu je to potrebno.
14. Spoj prema bilo kojem od zahtjeva 1-8 naznačen time da je za liječenje poremećaja koji je posredovan sa aspartatnom proteazom.
15. Spoj prema zahtjevu 14, naznačen time da navedeni poremećaj je hipertenzija, kongestivno zatajenje srca, srčana hipertrofija, srčana fibroza, kardiomiopatija nakon infarkta, nefropatija, vaskulopatija i neuropatija, bolest koronarnih krvnih žila, postoperativna hipertenzija, restenoza nakon angioplastike, povišeni intraokularni tlak, glaukom, nenormalan vaskularni rast, hiperaldosteronizam, stanje anksioznosti, ili kognitivni poremećaj.
16. Spoj prema zahtjevu 14, naznačen time da nadalje sadrži davanje jednog ili više dodatnih sredstava koja su odabrana iz skupine koja sadrži α-blokatore, β-blokator, blokator kalcijevog kanala, diuretik, inhibitor angiotenzin konvertirajućeg enzima, dvostruki angiotenzin konvertirajući enzim i neutralni inhibitor endopeptidaze, blokator receptora angiotenzina, dvostruki blokator receptora angiotenzina i antagonist receptora endotelina, inhibitor aldosteron sintaze, antagonist receptora aldosterona, te antagonist receptora endotelina.
17. Spoj prema zahtjevu 14, naznačen time da aspartatna proteaza je β-sekretaza, plazmepsin ili HIV proteaza.
18. Uporaba spoja prema bilo kojem od zahtjeva 1-8 naznačena time da je za proizvodnju lijeka za liječenje poremećaja koji je posredovan sa aspartatnom proteazom kod subjekta.
19. Spoj koji je prikazan sa strukturnom formulom koja je odabrana od:
[image]
[image]
[image]
[image]
i
[image]
ili njegova sol, naznačen time da:
R2 je H ili alkil; te
E je H ili Boc.
20. Spoj prema zahtjevu 19, naznačen time da je spoj odabran iz skupine koja sadrži:
tert-butil (S)-1-amino-3-((R)-tetrahidro-2H-piran-3-il)propan-2-ilkarbamat;
tert-butil (S)-1-amino-3-((R)-tetrahidro-2H-piran-3-il)propan-2-il(metil)karbamat;
tert-bultil-1-amino-3-(tetrahidro-2H-piran-3-il)propan-2-ilkarbamat; te
tert-butil-1-amino-3-(tetrahidro-2H-piran-3-il)propan-2-il(metil)karbamat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84529106P | 2006-09-18 | 2006-09-18 | |
| PCT/US2007/020164 WO2008036247A1 (en) | 2006-09-18 | 2007-09-18 | Renin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20130144T1 HRP20130144T1 (en) | 2013-03-31 |
| HRP20130144T4 true HRP20130144T4 (hr) | 2013-10-25 |
Family
ID=38786973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130144TT HRP20130144T4 (hr) | 2006-09-18 | 2013-02-20 | Inhibitori renina |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8198453B2 (hr) |
| EP (2) | EP2581366A1 (hr) |
| JP (1) | JP5331695B2 (hr) |
| KR (1) | KR20090064582A (hr) |
| CN (1) | CN101528723B (hr) |
| AR (1) | AR062797A1 (hr) |
| AU (1) | AU2007297729C1 (hr) |
| BR (1) | BRPI0718460A2 (hr) |
| CA (1) | CA2663263A1 (hr) |
| CL (1) | CL2007002689A1 (hr) |
| DK (1) | DK2074108T3 (hr) |
| ES (1) | ES2400009T7 (hr) |
| HK (1) | HK1129115A1 (hr) |
| HR (1) | HRP20130144T4 (hr) |
| MX (1) | MX2009002740A (hr) |
| NZ (1) | NZ575803A (hr) |
| PE (1) | PE20080843A1 (hr) |
| PL (1) | PL2074108T6 (hr) |
| PT (1) | PT2074108E (hr) |
| RS (1) | RS52679B (hr) |
| SI (1) | SI2074108T1 (hr) |
| TW (1) | TWI403510B (hr) |
| WO (1) | WO2008036247A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5067968B2 (ja) * | 2004-10-07 | 2012-11-07 | ビテ ファーマシューティカルズ， インコーポレイテッド | ジアミノアルカンアスパラギン酸プロテアーゼ阻害剤 |
| TWI411607B (zh) | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
| CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| EP2081927B1 (en) * | 2006-09-18 | 2011-08-17 | Vitae Pharmaceuticals, Inc. | Piperidine derivatives as renin inhibitors |
| US20100317697A1 (en) * | 2007-06-20 | 2010-12-16 | Baldwin John J | Renin Inhibitors |
| EP2170815A2 (en) * | 2007-06-20 | 2010-04-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| US20110160300A1 (en) * | 2008-06-20 | 2011-06-30 | Marlys Hammond | Renin Inhibitors and Methods of Use Thereof |
| MX2010014557A (es) * | 2008-06-26 | 2011-02-15 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo. |
| US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
| AU2016256776B2 (en) * | 2009-03-18 | 2018-04-12 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| JP2012520890A (ja) | 2009-03-18 | 2012-09-10 | インカーダ セラピューティクス， インコーポレイテッド | 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 |
| AU2013248242B2 (en) * | 2009-03-18 | 2016-08-18 | Incarda Therapeutics, Inc | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| AR077692A1 (es) * | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
| IL260335B2 (en) | 2016-02-01 | 2023-10-01 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation |
| AU2018266199A1 (en) | 2017-05-10 | 2019-11-07 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3071618A (en) | 1956-02-02 | 1963-01-01 | Pfizer & Co C | Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines |
| US4136163A (en) | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
| GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
| JPS5115098A (ja) | 1974-07-26 | 1976-02-06 | Asahi Chemical Ind | Akurirukeiseniseihinno shorihoho |
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4594343A (en) | 1984-10-19 | 1986-06-10 | Shanklin Jr James R | 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles |
| GB8810067D0 (en) | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| US5821232A (en) | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
| ES2097208T3 (es) | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
| DE4018070A1 (de) | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| JP3112290B2 (ja) | 1990-12-14 | 2000-11-27 | メレルダウファーマスーティカルズ インコーポレイテッド | 抗アレルギー化合物 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| JP3357879B2 (ja) | 1992-02-13 | 2002-12-16 | メレルダウファーマス−ティカルズ インコーポレイテッド | ピペリジニルチア環状誘導体類 |
| HUT70952A (en) | 1992-06-10 | 1995-11-28 | Eastman Kodak Co | Surface modified nanoparticles based on nosteroidal inflammatory drugs, process for preparing them and pharmaceutical compns. contg. them |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| EP0773921B1 (en) | 1994-07-29 | 1999-12-01 | Abbott Laboratories | Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| NZ315677A (en) | 1995-09-07 | 2000-02-28 | F | 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| WO1998054179A1 (en) | 1997-05-29 | 1998-12-03 | Eli Lilly And Company | Process for preparing heterocyclic compounds |
| WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| GB9826540D0 (en) * | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
| DE60027131D1 (de) | 1999-01-06 | 2006-05-18 | Us Gov Health & Human Serv | Inhibitoren für asparagin-proteasen |
| JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | Ｎ−置換ピペリジン誘導体 |
| US7071184B2 (en) | 2000-03-21 | 2006-07-04 | Smithkline Beecham Corporation | Protease inhibitors |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| OA12698A (en) | 2001-07-11 | 2006-06-22 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl)substituted alkylamidecompounds. |
| IL161881A0 (en) | 2001-11-08 | 2005-11-20 | Upjohn Co | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| AU2003231766A1 (en) | 2002-04-26 | 2003-11-10 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| WO2004002483A1 (en) | 2002-06-27 | 2004-01-08 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease |
| US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| JP2005538177A (ja) | 2002-09-10 | 2005-12-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | アルツハイマー病処置用置換アミノエーテル化合物 |
| NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CN1890239A (zh) * | 2003-12-05 | 2007-01-03 | 埃科特莱茵药品有限公司 | 二氮杂二环壬烯及带有新的侧链的四氢吡啶衍生物 |
| US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| US20060063930A1 (en) | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
| JP5067968B2 (ja) * | 2004-10-07 | 2012-11-07 | ビテ ファーマシューティカルズ， インコーポレイテッド | ジアミノアルカンアスパラギン酸プロテアーゼ阻害剤 |
| WO2006079988A1 (en) * | 2005-01-28 | 2006-08-03 | Actelion Pharmaceuticals Ltd | 7- {4- [2- (2 , 6-dichl0r0-4-methylphen0xy) ethoxy] phenyl}-3 , 9-diazabicyclo [3 .3 . 31] non - 6-ene- s- carboxylic acid cyclopropyl- (2 , 3-dimethylbenzyd amide as inhibitors of renin for the treatment of hypertension |
| JP2008528691A (ja) * | 2005-02-02 | 2008-07-31 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン |
| CN101175724B (zh) | 2005-05-19 | 2011-12-07 | 安斯泰来制药有限公司 | 吡咯烷衍生物或其盐 |
| TWI411607B (zh) * | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| EP2081927B1 (en) | 2006-09-18 | 2011-08-17 | Vitae Pharmaceuticals, Inc. | Piperidine derivatives as renin inhibitors |
| CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| US20100317697A1 (en) | 2007-06-20 | 2010-12-16 | Baldwin John J | Renin Inhibitors |
| EP2170815A2 (en) | 2007-06-20 | 2010-04-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
| US20110160300A1 (en) | 2008-06-20 | 2011-06-30 | Marlys Hammond | Renin Inhibitors and Methods of Use Thereof |
| MX2010014557A (es) | 2008-06-26 | 2011-02-15 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo. |
| AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
-
2007
- 2007-09-14 CL CL200702689A patent/CL2007002689A1/es unknown
- 2007-09-17 TW TW096134810A patent/TWI403510B/zh not_active IP Right Cessation
- 2007-09-17 AR ARP070104098A patent/AR062797A1/es unknown
- 2007-09-17 PE PE2007001252A patent/PE20080843A1/es not_active Application Discontinuation
- 2007-09-18 ES ES07838381T patent/ES2400009T7/es active Active
- 2007-09-18 SI SI200731161T patent/SI2074108T1/sl unknown
- 2007-09-18 PT PT78383817T patent/PT2074108E/pt unknown
- 2007-09-18 MX MX2009002740A patent/MX2009002740A/es active IP Right Grant
- 2007-09-18 EP EP11186691.9A patent/EP2581366A1/en not_active Withdrawn
- 2007-09-18 KR KR1020097007791A patent/KR20090064582A/ko not_active Application Discontinuation
- 2007-09-18 CA CA002663263A patent/CA2663263A1/en not_active Withdrawn
- 2007-09-18 PL PL07838381T patent/PL2074108T6/pl unknown
- 2007-09-18 US US12/311,012 patent/US8198453B2/en not_active Expired - Fee Related
- 2007-09-18 AU AU2007297729A patent/AU2007297729C1/en not_active Ceased
- 2007-09-18 JP JP2009528331A patent/JP5331695B2/ja not_active Expired - Fee Related
- 2007-09-18 WO PCT/US2007/020164 patent/WO2008036247A1/en active Application Filing
- 2007-09-18 CN CN2007800391198A patent/CN101528723B/zh not_active Expired - Fee Related
- 2007-09-18 NZ NZ575803A patent/NZ575803A/en not_active IP Right Cessation
- 2007-09-18 BR BRPI0718460-3A patent/BRPI0718460A2/pt not_active IP Right Cessation
- 2007-09-18 DK DK07838381.7T patent/DK2074108T3/da active
- 2007-09-18 EP EP07838381.7A patent/EP2074108B3/en active Active
- 2007-09-18 RS RS20130064A patent/RS52679B/en unknown
-
2009
- 2009-10-05 HK HK09109173.1A patent/HK1129115A1/xx not_active IP Right Cessation
-
2012
- 2012-05-11 US US13/469,562 patent/US8580823B2/en not_active Expired - Fee Related
-
2013
- 2013-02-20 HR HRP20130144TT patent/HRP20130144T4/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130144T4 (hr) | Inhibitori renina | |
| JP2010503682A5 (hr) | ||
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| CL2011002604A1 (es) | Compuestos derivados de n-(cianometil)-4-(sulfonil)pirrolidina-2-carboxamida, inhibidores de catepsina s o l; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, aterosclerosis, aneurismo aortico abdominal, enfermedades arteriales periferica o la nefropatia diabetica. | |
| RU2009127642A (ru) | 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы | |
| RU2008150752A (ru) | Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| JP2005531516A5 (hr) | ||
| PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
| WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
| PE20060999A1 (es) | Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| PE20080077A1 (es) | Derivados de sulfonilfenilo como antagonistas del receptor de il-8 | |
| ES2572155T3 (es) | Compuestos insecticidas | |
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| WO2007125310A3 (en) | Pharmaceutical combinations of pk inhibitors and other active agents | |
| AR085689A1 (es) | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 | |
| RU2011138970A (ru) | Активаторы растворимой гуанилатциклазы | |
| NO20054951L (no) | Prostaglandinanaloger som EP4-reseptorantagonister | |
| AR057849A1 (es) | Dialurrea para el tratamiento de hipertension pulmonar | |
| NO20090075L (no) | Nye CXCR2 inhibitorer | |
| PE20050552A1 (es) | Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp | |
| NO20070445L (no) | Pyrimidinderivater. | |
| PE20140858A1 (es) | Derivados de piperidina como inhibidores de renina | |
| ME00479B (me) | Lijek za profilaksu i tretman arterioskleroze i hipertenzije |